196 related articles for article (PubMed ID: 35817678)
1. Progression of retinopathy with glucagon-like peptide-1 receptor agonists with cardiovascular benefits in type 2 diabetes - A systematic review and meta-analysis.
Yoshida Y; Joshi P; Barri S; Wang J; Corder AL; O'Connell SS; Fonseca VA
J Diabetes Complications; 2022 Aug; 36(8):108255. PubMed ID: 35817678
[TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide 1-receptor agonists and A1c: Good for the heart but less so for the eyes?
Albert SG; Wood EM; Ahir V
Diabetes Metab Syndr; 2023 Jan; 17(1):102696. PubMed ID: 36596264
[TBL] [Abstract][Full Text] [Related]
3. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.
Dicembrini I; Nreu B; Scatena A; Andreozzi F; Sesti G; Mannucci E; Monami M
Acta Diabetol; 2017 Oct; 54(10):933-941. PubMed ID: 28748377
[TBL] [Abstract][Full Text] [Related]
4. Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis.
Sabouret P; Bocchino PP; Angelini F; D'Ascenzo F; Galati G; Fysekidis M; DE Ferrari GM; Fischman DL; Bhatt DL; Biondi-Zoccai G
Minerva Cardiol Angiol; 2023 Apr; 71(2):199-207. PubMed ID: 35195376
[TBL] [Abstract][Full Text] [Related]
5. Glucagon-Like Peptide-1 Receptor Agonist and Risk of Diabetic Retinopathy in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials.
Jiao X; Peng P; Zhang Q; Shen Y
Clin Drug Investig; 2023 Dec; 43(12):915-926. PubMed ID: 37938535
[TBL] [Abstract][Full Text] [Related]
6. Risk of diabetic retinopathy and diabetic macular oedema with sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists in type 2 diabetes: a real-world data study from a global federated database.
Eleftheriadou A; Riley D; Zhao SS; Austin P; Hernández G; Lip GYH; Jackson TL; Wilding JPH; Alam U
Diabetologia; 2024 Jul; 67(7):1271-1282. PubMed ID: 38584180
[TBL] [Abstract][Full Text] [Related]
7. Indirect comparison of glucagon like peptide-1 receptor agonists regarding cardiovascular safety and mortality in patients with type 2 diabetes mellitus: network meta-analysis.
Alfayez OM; Almohammed OA; Alkhezi OS; Almutairi AR; Al Yami MS
Cardiovasc Diabetol; 2020 Jun; 19(1):96. PubMed ID: 32571416
[TBL] [Abstract][Full Text] [Related]
8. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists.
Lin TY; Kang EY; Shao SC; Lai EC; Garg SJ; Chen KJ; Kang JH; Wu WC; Lai CC; Hwang YS
Diabetes Metab J; 2023 May; 47(3):394-404. PubMed ID: 36872060
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of diabetic retinopathy events associated with glucose-lowering drugs in patients with type 2 diabetes mellitus: A network meta-analysis.
Tang H; Li G; Zhao Y; Wang F; Gower EW; Shi L; Wang T
Diabetes Obes Metab; 2018 May; 20(5):1262-1279. PubMed ID: 29369494
[TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 (GLP-1) receptor agonists and cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of double-blind, randomized, placebo-controlled clinical trials.
Qin J; Song L
BMC Endocr Disord; 2022 May; 22(1):125. PubMed ID: 35546664
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
[TBL] [Abstract][Full Text] [Related]
12. Is it Time to Expand Glucagon-like Peptide-1 Receptor Agonist Use for Weight Loss in Patients Without Diabetes?
Updike WH; Pane O; Franks R; Saber F; Abdeen F; Balazy DD; Carris NW
Drugs; 2021 Jun; 81(8):881-893. PubMed ID: 33929717
[TBL] [Abstract][Full Text] [Related]
13. Safety issues with glucagon-like peptide-1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): Data from randomized controlled trials.
Monami M; Nreu B; Scatena A; Cresci B; Andreozzi F; Sesti G; Mannucci E
Diabetes Obes Metab; 2017 Sep; 19(9):1233-1241. PubMed ID: 28244632
[TBL] [Abstract][Full Text] [Related]
14. Major cardiovascular events, heart failure, and atrial fibrillation in patients treated with glucagon-like peptide-1 receptor agonists: An updated meta-analysis of randomized controlled trials.
Nreu B; Dicembrini I; Tinti F; Sesti G; Mannucci E; Monami M
Nutr Metab Cardiovasc Dis; 2020 Jun; 30(7):1106-1114. PubMed ID: 32448716
[TBL] [Abstract][Full Text] [Related]
15. Effects of GLP-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and meta-analysis.
Kelly M; Lewis J; Rao H; Carter J; Portillo I; Beuttler R
Pharmacotherapy; 2022 Dec; 42(12):921-928. PubMed ID: 36271706
[TBL] [Abstract][Full Text] [Related]
16. Effect of Glucagon-like Peptide-1 Receptor Agonists on All-cause Mortality and Cardiovascular Outcomes: A Meta-analysis.
Peterson SC; Barry AR
Curr Diabetes Rev; 2018; 14(3):273-279. PubMed ID: 28413990
[TBL] [Abstract][Full Text] [Related]
17. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
Li Y; Rosenblit PD
Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
[TBL] [Abstract][Full Text] [Related]
18. GLP-1-ra and heart failure-related outcomes in patients with and without history of heart failure: an updated systematic review and meta-analysis.
Villaschi A; Ferrante G; Cannata F; Pini D; Pagnesi M; Corrada E; Reimers B; Mehran R; Federici M; Savarese G; Metra M; Condorelli G; Stefanini GG; Chiarito M
Clin Res Cardiol; 2024 Jun; 113(6):898-909. PubMed ID: 38252145
[TBL] [Abstract][Full Text] [Related]
19. Heterogeneity of antidiabetic treatment effect on the risk of major adverse cardiovascular events in type 2 diabetes: a systematic review and meta-analysis.
D'Andrea E; Kesselheim AS; Franklin JM; Jung EH; Hey SP; Patorno E
Cardiovasc Diabetol; 2020 Sep; 19(1):154. PubMed ID: 32993654
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis.
Htike ZZ; Zaccardi F; Papamargaritis D; Webb DR; Khunti K; Davies MJ
Diabetes Obes Metab; 2017 Apr; 19(4):524-536. PubMed ID: 27981757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
